A Phage-Derived Protein Reveals a New Strategy to Block Bacterial Cell Wall Synthesis

A research team at the Nara Institute of Science and Technology (NAIST) in Japan has uncovered how a small protein produced by a bacteriophage can interfere with an essential mechanism of bacterial survival. The discovery, reported by The Microbiologist on November 10, 2026, focuses on SglPP7, a phage-derived lysis protein that blocks MurJ, a membrane transporter involved in bacterial cell wall synthesis.

Structural illustration showing how the bacteriophage-derived protein SglPP7 binds to MurJ and locks the transporter in an outward-facing conformation, disrupting lipid II transport and bacterial cell wall synthesis. Adapted from Hosoda et al., PLOS Biology (2026).

The work was led by researchers from NAIST’s Laboratory of Structural Life Science, including Professor Tomoya Tsukazaki and Assistant Professor Hidetaka Kohga, together with colleagues from the institute and the Japan Synchrotron Radiation Research Institute. Their findings were published in PLOS Biology on October 27, 2026.

MurJ plays an essential role in the construction of the bacterial cell wall. It transports lipid II, a precursor required for peptidoglycan synthesis, from the inner side of the cytoplasmic membrane towards the periplasm. This process depends on changes in the transporter’s three-dimensional structure, allowing it to alternate between different conformations during the transport cycle. Disrupting MurJ therefore interferes with an essential step in cell wall production.

The researchers investigated how SglPP7, a small single-gene lysis protein encoded by bacteriophage PP7, interacts with this transporter. Using cryo-electron microscopy, they determined the structure of the MurJ–SglPP7 complex and showed how the phage protein binds to the transporter. Its C-terminal region penetrates an internal cavity in MurJ, stabilising the protein in an outward-facing conformation and preventing the structural movements required for normal lipid transport.

The study also compared SglPP7 with other phage-derived proteins known to target MurJ, including LysM from bacteriophage M and SglCJ3. Although these proteins have substantially different amino acid sequences and interact with MurJ through distinct binding arrangements, they appear to converge on a similar outcome: stabilising the transporter in an outward-facing state. This suggests that different bacteriophages may have independently evolved molecular strategies to disable the same essential bacterial target.

The findings are particularly relevant to the search for new antibacterial targets. MurJ is indispensable for bacterial cell wall biosynthesis, making its inhibition an attractive strategy for disrupting bacterial viability. Phage-derived lysis proteins such as SglPP7 could therefore provide molecular templates for the design of new antibacterial molecules, including engineered proteins capable of targeting essential bacterial processes.

However, the research remains at the fundamental stage. It does not demonstrate the effectiveness of SglPP7 as a therapeutic agent in infected animals or humans, nor does it describe a new phage therapy treatment. Instead, it provides structural and functional information that could support future efforts to develop antibacterial compounds targeting MurJ.

The study also highlights the broader value of bacteriophages as a source of antibacterial molecules. Beyond their ability to infect and destroy bacterial cells, phages encode proteins that can selectively interfere with essential host functions. Understanding these mechanisms may help researchers identify new ways to exploit bacterial vulnerabilities, particularly as resistance to conventional antibiotics continues to increase.

By revealing how SglPP7 disables MurJ, the NAIST team adds another example of how phage biology can inform antibacterial drug discovery. The work provides a molecular starting point for exploring MurJ inhibition and demonstrates how proteins evolved by bacteriophages may inspire future strategies against bacterial pathogens.



References :

Hosoda, K. et al. (2026). “Structural basis for inhibition of the lipid flippase MurJ by phage lysis protein SglPP7 suggests convergent evolution with other Sgl peptides.” PLOS Biology, 24(10), e3004039. https://doi.org/10.1371/journal.pbio.3004039

Nara Institute of Science and Technology (October 28, 2026). “A common strategy used by different viruses to target bacterial vulnerabilities.” Official institutional announcement.

The Microbiologist (November 10, 2026). “Phage protein reveals a new way to disable an essential bacterial transporter.”

Comments

Most Consulted Articles

Bacteriophages Disarm Inflammation-Associated E. coli Without Erasing the Gut Microbiome in IBD

🌐 PhageAtLabs® — a global interactive mapping of academic laboratories in phage research.

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

The Phage Therapy in the spotlight !

Phagos Launches CAPHARD, a 900-Million-Parameter AI Model to Predict Phage–Bacteria Interactions